Eli Lilly's combination antibody therapy to fight COVID-19 has been granted by FDA



Lilly's combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January.


Lilly said the therapy will be available immediately.


Check out the full article right here.

0 comments